Invatec s.r.l. (Invatec), a cardiovascular devices company, announced that it has entered into a strategic distribution agreement with Cardiovascular Systems Inc. (CSI), a developer of interventional treatment systems for vascular disease. As per terms of the agreement, CSI will distribute Invatec's FDA-cleared percutaneous transluminal angioplasty balloon catheter product line. The agreement will greatly expand Invatec's US sales presence, allowing more physicians access to Invatec's products.

“We are excited about the distribution agreement with CSI,” said Jack Springer, president of Invatec USA. “The strength and size of CSI’s sales force, coupled with its proven track record of success in reaching a wide physician audience, will be instrumental in helping us to accelerate our market potential. Our primary objective is to place our innovative product portfolio into the hands of physicians and partnering with CSI provides a great opportunity to achieve this goal.”

“CSI is committed to developing and offering products specifically designed to treat peripheral artery disease (PAD) and to prevent the trauma and costs associated with limb amputation,” said David L. Martin, CSI president and chief executive officer. “The innovative Invatec products complement and expand our product portfolio, as well as enhance the productivity of our national sales team. These product additions are in line with our mission to provide physicians with the tools they need to treat PAD.”